Contineum Therapeutics (CTNM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CTNM Contineum Therapeutics

Watchlist

15.730
+1.640+11.64%

Trading Nov 25 15:30 ET

405.48MMarket Cap-14007P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
BusinesswireNov 25 08:05 ET
Express News | Contineum Therapeutics Inc - Expects $213.9 Mln Cash to Fund Operations Through 2027
ReutersNov 18 08:05 ET
Express News | Contineum Therapeutics Inc - Phase 1B Study for Pipe-791 to Begin in Q1 2025
ReutersNov 18 08:05 ET
Express News | Contineum Therapeutics Inc: Phase 1B Study for Potential Treatment of Osteoarthritis and Low Back Pain Expected to Commence in Q1 of 2025
ReutersNov 18 08:05 ET
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Business WireNov 18 08:05 ET
Express News | Contineum Therapeutics Expands Clinical Development of Pipe-791 With FDA Authorization of Its Investigational New Drug (Ind) Application for Chronic Pain
ReutersNov 18 08:05 ET

Comments

Pinchie McPincher

Apr 19 03:23

$Contineum Therapeutics (CTNM.US)$what am i missing?

Jaguar8

Apr 4 22:56

$Contineum Therapeutics (CTNM.US)$
NEWS
Contineum Therapeutics, Inc. announces pricing of IPO, offering 6,875,000 shares of Class A common stock at $16.00 per share, expecting gross proceeds of $110.0 million. Shares to trade on Nasdaq under symbol 'CTNM'.